BeyondSpring (NASDAQ:BYSI) Stock Price Down 4.8% – Time to Sell?
by Michael Walen · The Markets DailyBeyondSpring Inc. (NASDAQ:BYSI – Get Free Report) fell 4.8% during mid-day trading on Friday . The stock traded as low as $1.56 and last traded at $1.57. 14,427 shares changed hands during trading, a decline of 42% from the average session volume of 24,960 shares. The stock had previously closed at $1.65.
Analysts Set New Price Targets
Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of BeyondSpring in a research report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.
View Our Latest Research Report on BeyondSpring
BeyondSpring Stock Down 4.8%
The firm has a market cap of $64.56 million, a PE ratio of -11.21 and a beta of 0.43. The stock’s fifty day simple moving average is $1.61 and its two-hundred day simple moving average is $1.65.
BeyondSpring (NASDAQ:BYSI – Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.49.
Institutional Investors Weigh In On BeyondSpring
A hedge fund recently raised its stake in BeyondSpring stock. Geode Capital Management LLC boosted its holdings in BeyondSpring Inc. (NASDAQ:BYSI – Free Report) by 16.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 368,682 shares of the company’s stock after purchasing an additional 53,198 shares during the quarter. Geode Capital Management LLC owned about 0.91% of BeyondSpring worth $601,000 at the end of the most recent quarter. 40.29% of the stock is owned by institutional investors and hedge funds.
About BeyondSpring
BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.
The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.